echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Broad Becomes CRIPSR Patent Owner Intellia Faces Patent Infringement

    Broad Becomes CRIPSR Patent Owner Intellia Faces Patent Infringement

    • Last Update: 2022-05-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    U.


    ATTR is caused by the accumulation of transthyretin in important tissues due to mutation or aging, so it is divided into two subtypes: hereditary and senile, mainly affecting the heart (ATTR-CM) and nerve tissue (FAP)


    High doses of NTLA-2001 appear to be more effective at lowering TTR levels than existing therapies, but this biomarker therapy needs to be translated into disease treatments that actually improve patients' quality of life


    Although one injection of Yongyi is a theoretical advantage, it is more difficult to reverse if rare toxic side effects occur.


    Coincidentally, the historical issue of patents resurfaced at the height of the technology's brilliance, as the patent lawsuit was destined to bring down the final round because of the importance of the technology


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.